Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer

Gut

Volumn 54, Issue 1, 2005, Pages 109-116

  Stoll, V ^b   Calleja, V ^b,c   Vassaux, G ^b   Downward, J ^c   Lemoine, N R ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AAA PROTEIN KINASE B; ADENOVIRUS VECTOR; GENE PRODUCT; GREEN FLUORESCENT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; N17 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P85BETA; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME REGULATION; GENE TARGETING; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT TRANSFORMATION; MOUSE; MUTANT; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSGENE; TUMOR CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL DIVISION; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 10844282781     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.046706     Document Type: Article

References (29)

1. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10.
2. Almoguera C, Shibota D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
3. Lemoine NR, Jain S, Hughes CM, et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992;102:230-6.
4. Ghaneh P, Kawesha A, Evans JD, et al. Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002;9:1-11.
5. Friess H, Guo XZ, Nan BC, et al. Growth factors and cytokines in pancreatic carcinogenesis. Ann N Y Acad Sci 1999;880:110-21.
6. Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994;370:527-32.
7. Anderson KE, Coadwell J, Stephens LR, et al. Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B. Curr Biol 1998;8:684-91.
8. Datta K, Bellacosa A, Chan TO, et al. Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J Biol Chem 1996;271:30835-9.
9. Dudek H, Datta SR, Franke TF, et al. Regulation of neuronal survival by the serine-threanine protein kinase Akt. Science 1997;275:661-5.
10. Khwaja A, Rodriguez-Viciana P, Wennstrom S, et al. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. Embo J 1997;16:2783-93.
11. Gille H, Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem 1999;274:22033-40.
12. Datta SR, Dudek H, Too X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
13. Brunei A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-08.
14. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
15. Bandar VM, Sweeney-Gotsch B, Andreeff M, et al. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002;1:989-97.
16. Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A 1996;93:3636-41.
17. Schlieman MG, Fahy BN, Ramsamooj R, et al. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003;89:2110-5.
18. Coffer PJ, Woodgett JR. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 1991;201:475-81.
19. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509-14.
20. Stacey DW, Feig LA, Gibbs JB. Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras. Mol Cell Biol 1991;11:4053-64.
21. Rodriguez-Viciana P, Warne PH, Khwaja A, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997;89:457-67.
22. Hlobilkova A, Guldberg P, Thullberg M, et al. Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity. Exp Cell Res 2000;256:571-7.
23. Bertrand L, Alessi DR, Deprez J, et al. Heart 6-phosphofructo-2-kinase activation by insulin results from Ser-466 and Ser-483 phosphorylation and requires 3-phosphoinositide-dependent kinase-1, but not protein kinase B. J Biol Chem 1999;274:30927-33.
24. van Weeren PC, de Bruyn KM, de Vries-Smits AM, et al. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem 1998;273:13150-6.
25. Aoki K, Yoshida T, Sugimura T, et al. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995;55:3810-16.
26. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002;2:243-7.
27. Oldham SM, Cox AD, Reynolds ER, et al. Ras, but not Src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade. Oncogene 1998;16:2565-73.
28. Stewart S, Guan KL. The dominant negative Ras mutant, N17Ras, can inhibit signaling independently of blocking Ras activation. J Biol Chem 2000;275:8854-62.
29. Ng SSW, Tsao MS, Chow S, et al. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000;60:5451-5.